Teriparatide Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Teriparatide Access in 2026

Teriparatide remains a cornerstone of anabolic osteoporosis therapy for patients at high fracture risk. Yet your patients may be reporting difficulty filling prescriptions — even though the medication is technically available. This briefing covers the current supply landscape, prescribing considerations, and practical tools to help your patients maintain access to therapy in 2026.

Supply Status and Timeline

As of early 2026, Teriparatide is not listed on the FDA or ASHP drug shortage databases. Both the brand-name product (Forteo, Eli Lilly) and FDA-approved generic teriparatide injections (Teva, Alvogen) are in active production and distribution.

However, several developments have affected real-world availability:

• Q1 2025: Eli Lilly implemented packaging and labeling changes for Forteo pens, including updated metric quantities and NDC numbers. This caused temporary billing discrepancies at pharmacies and with payer adjudication systems.
• Mid-2025: Drug data compendia updated to reflect new Forteo packaging, resolving most billing issues.
• 2025-2026: Generic teriparatide from Teva and Alvogen continues to gain formulary placement, improving overall supply diversity.

While there is no formal shortage, the specialty distribution model and payer requirements create persistent access friction for many patients.

Prescribing Implications

When initiating or continuing Teriparatide therapy, consider the following access factors:

Prior Authorization and Step Therapy

The majority of commercial and Medicare Part D plans require prior authorization for Teriparatide. Common requirements include:

• Documented diagnosis of osteoporosis with T-score ≤ -2.5 or history of fragility fracture
• Trial and failure of, or contraindication to, at least one bisphosphonate (step therapy)
• Confirmation that prescriber is an appropriate specialist (endocrinology, rheumatology, or similar)
• Documentation that treatment duration will not exceed 24 months

Proactive submission of prior authorization — ideally before the patient's current supply runs out — can prevent treatment gaps. Many specialty pharmacies offer PA support as part of their services.

Brand vs. Generic Considerations

Generic teriparatide is FDA-approved and therapeutically equivalent to Forteo. Key points for prescribing:

• Generic formulation is identical: 600 mcg/2.4 mL prefilled pen, 28 doses of 20 mcg
• Some payers have moved generic teriparatide to preferred formulary status, with Forteo requiring exceptions or higher copays
• Prescribing generic teriparatide (rather than DAW for Forteo) may improve formulary access and reduce patient costs
• Verify with the patient's pharmacy or specialty pharmacy which product their plan covers

Current Availability Picture

Teriparatide's availability challenges are primarily structural rather than supply-based:

• Retail pharmacy stocking: Most chain pharmacies do not routinely stock Teriparatide due to cold chain requirements and low per-store volume. Patients accustomed to using their local pharmacy may encounter "not in stock" responses that feel like a shortage.
• Specialty pharmacy distribution: The majority of Teriparatide prescriptions are filled through specialty pharmacies with cold chain shipping capabilities. Directing patients to specialty pharmacy channels — either insurer-mandated or independently — typically resolves availability issues.
• Independent pharmacies: Some independent pharmacies will special-order Teriparatide and may provide more flexible service than chain outlets.

Cost and Access Landscape

Cost remains a significant barrier for many patients:

• Brand Forteo cash price: $3,100–$5,400 per pen (28-day supply)
• Generic teriparatide cash price: ~$3,400 per pen (retail); as low as $1,146 with discount coupons
• Forteo copay card: As low as $4/month for eligible commercially insured patients
• Teva savings program: Copay assistance available for generic teriparatide
• Lilly Cares Foundation PAP: Provides Forteo at no cost for qualifying uninsured/underinsured patients

Medicare patients cannot use manufacturer copay cards per federal anti-kickback regulations. For these patients, the Lilly Cares PAP, state pharmaceutical assistance programs, and resources from NeedyMeds or RxAssist may be appropriate.

Tools and Resources for Your Practice

Several tools can help you and your staff support patients navigating Teriparatide access:

• Medfinder for Providers: A free tool that allows providers and staff to search for pharmacies with Teriparatide in stock by location. Useful for directing patients to specific pharmacies rather than sending them on a phone-based scavenger hunt.
• Specialty pharmacy referral: Establishing relationships with 1-2 specialty pharmacies experienced with osteoporosis medications can streamline the dispensing process for your patients.
• PA templates: Developing standardized prior authorization letters for Teriparatide — with fields for DXA results, fracture history, and bisphosphonate trial documentation — can reduce administrative burden.

Alternative Agents

When Teriparatide is not accessible or appropriate, consider the following:

• Abaloparatide (Tymlos): PTHrP analog with similar anabolic mechanism. Daily SC injection, up to 24 months. May have slightly lower hypercalcemia incidence. FDA-approved for postmenopausal and male osteoporosis at high fracture risk.
• Romosozumab (Evenity): Anti-sclerostin monoclonal antibody with dual anabolic/antiresorptive mechanism. Monthly SC injection for 12 months. Carries boxed warning for cardiovascular events — contraindicated in patients with recent MI or stroke.
• Denosumab (Prolia): Anti-RANKL monoclonal antibody. SC injection q6 months. Antiresorptive only. Important: do not discontinue without transitioning to bisphosphonate (rebound vertebral fractures documented).
• Bisphosphonates: Alendronate, risedronate (oral), zoledronic acid (IV yearly). First-line, most cost-effective. Appropriate for maintaining bone density gains after completing anabolic therapy.

For a patient-facing comparison, see our article on alternatives to Teriparatide.

Looking Ahead

The generic teriparatide market is expected to continue expanding, which should improve formulary access and drive down costs. However, the fundamental challenges of specialty distribution, cold chain logistics, and payer barriers will persist. Building systematic approaches to prior authorization, specialty pharmacy partnerships, and patient education will continue to be the most effective strategies for ensuring uninterrupted therapy.

Final Thoughts

Teriparatide remains one of our most effective tools for building bone in high-risk osteoporosis patients. The "shortage" your patients are experiencing is primarily an access and logistics challenge, not a supply problem. By leveraging tools like Medfinder for Providers, streamlining prior authorization workflows, and building specialty pharmacy relationships, you can help ensure your patients maintain access to this critical therapy.

For a patient-focused version of this information, share our patient shortage update or our guide on how to find Teriparatide in stock.